Orchid Pharma has scheduled its 33rd Annual General Meeting for September 29, 2026. The meeting will address the ratification of a ₹400 crore related-party transaction limit with Otsuka Chemicals (India) Private Limited and the appointment of Mr. Arjun Dhanuka as Whole-Time Director.

The Board convened on September 3, 2026, to approve these matters in compliance with SEBI Listing Regulations. The AGM will be held via Video Conferencing/Other Audio Visual Means (VC/OAVM). The Annual Report for FY25-26, containing the notice, was dispatched to members as on September 4, 2026.

Related Party Transaction Approval

Shareholders are asked to approve material related-party transactions with M/s. Otsuka Chemicals (India) Private Limited for FY27. The proposed ceiling is ₹400 crore for the purchase of goods, specifically the key raw material GCLE (Advanced Cephalosporin Drug Intermediate).

Otsuka is the sole approved source for GCLE. The relationship arises because Mr. Manish Dhanuka (Managing Director) and Mr. Mridul Dhanuka (Whole-Time Director) are directors/members of Otsuka. Transactions in Q1FY26 stood at ₹6,317.48 lakh, while total FY25-26 purchases were ₹24,498 lakh.

Leadership Appointments

Mr. Arjun Dhanuka will serve as Whole-Time Director from September 3, 2026, to September 2, 2031. His monthly salary is set at ₹8 lakh with a 10% annual increment. He previously served as a Non-Executive Non-Independent Director.

Additionally, Mr. Mridul Dhanuka retires by rotation and offers himself for reappointment as Whole-Time Director.

Cost Auditor & Logistics

M/s. J Karthikeyan & Associates was appointed as Cost Auditor for FY27. Shareholders must ratify their remuneration of ₹3.5 lakh plus taxes.

The remote e-voting window opens on September 26, 2026, at 9:00 am and closes on September 28, 2026, at 5:00 pm. The record date for voting eligibility is September 22, 2026.

Orchid Pharma Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY26 to the National Stock Exchange and BSE. The filing covers the financial year ended March 31, 2026.

Orchid Pharma disclosed that its core business activity, the manufacture and sales of Active Pharmaceutical Ingredients and products, accounts for 97% of the entity's turnover. The report is prepared on a standalone basis.

General Disclosures

The company, incorporated on July 1, 1992, operates from its registered office in Chengalpattu, Tamil Nadu. The paid-up capital stands at ₹50.7 crore as per the disclosures. Kapil Dayya, Company Secretary and Compliance Officer, served as the point of contact for queries regarding the report.

Reporting Scope

The BRSR does not include an external assurance provider or a specified type of assurance. The disclosures focus strictly on the listed entity's standalone performance and sustainability metrics for the period.